Agilent CEO Mike McMullen recently said the market hasn't developed as expected, and Agilent doesn't see a way for Resolution Bioscience to become profitable.

BING NEWS:
  • Resolution’s £64M series B to advance macrophage cell therapy
    I/II trial of its autologous engineered macrophage cell therapy, RTX-001, in the treatment of end-stage liver disease and has raised £63.5 million (US$83.3 million) to complete the study and to add ...
    10/3/2024 - 6:25 am | View Link
  • More

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News